| ||||||||||||||||
| ||||||||||||||||
— Merck —Top tagsYou have executed a tag search on The Deal Newsweekly. To the right you will find a comprehensive list of stories tagged "Merck." Below are the most-popular tags for The Deal Newsweekly. On the right of the page you will find a search box to dig deeper into our content.
Community
 Entries tagged "Merck"The marriage of theory and practiceAbigail Barrow and Steven Shapin on the interaction of science, technology and economic development. A whole new ballgameRecent big-ticket pharma deals illustrate the evolution of financing outs and breakup fees. Paging Dr. SchollThe consumer-products subplot in the pharmaceutical megamergers. Little pharma bluesAs the economy foundered, drug industry insiders looked forward to an M&A frenzy. But with a few exceptions, deals occurred only at the top of the food chain. Merck, Schering play follow the pharmaDamian Ridealgh and other Fried Frank attorneys advised Merck on its deal for Schering. Abbott leads the biotech waveSkadden's Brian McCarthy led a team advising AMO in its sale to Abbott Labs. They need a new drugExpect Big Pharma to go shopping in biotechland, but with an eye for fire sales. Strength in numbersGoldman Sachs' Susan Scher. This won't hurt a bitAn examination of U.S. healthcare under the Obama administration. Litigation riskFASB weighs requiring companies to estimate their exposure to legal damages; business tries to bury the idea. Merck-Schering-BayerAfter it failed to win German birth-control maker Schering AG in 2006, drug titan Merck KGaA put its generics division on the block and has sold it to Mylan Laboratories Inc. for $6.6 billion. The deal nearly triples Pittsburgh-based Mylan Labs' revenue. | ||||||||||||||||
|
|
|
|
|
